X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lenalidomide (3182) 3182
index medicus (2756) 2756
humans (2525) 2525
hematology (1765) 1765
oncology (1721) 1721
multiple myeloma (1676) 1676
bortezomib (1150) 1150
male (1127) 1127
thalidomide - analogs & derivatives (1119) 1119
female (1112) 1112
multiple myeloma - drug therapy (1057) 1057
aged (1028) 1028
thalidomide (1007) 1007
middle aged (982) 982
dexamethasone (782) 782
treatment outcome (710) 710
therapy (697) 697
antineoplastic combined chemotherapy protocols - therapeutic use (678) 678
adult (649) 649
stem-cell transplantation (639) 639
thalidomide - therapeutic use (615) 615
thalidomide - administration & dosage (561) 561
antineoplastic agents - therapeutic use (531) 531
survival (524) 524
lenalidomide plus dexamethasone (523) 523
cancer (514) 514
care and treatment (507) 507
aged, 80 and over (497) 497
chemotherapy (460) 460
transplantation (440) 440
multiple myeloma - therapy (389) 389
multiple-myeloma (373) 373
prognosis (370) 370
thalidomide - adverse effects (360) 360
multiple myeloma - pathology (347) 347
hematology, oncology and palliative medicine (330) 330
dexamethasone - administration & dosage (326) 326
medicine & public health (311) 311
combination (310) 310
multiple myeloma - mortality (308) 308
pharmacology & pharmacy (300) 300
drug therapy (299) 299
recurrence (293) 293
open-label (285) 285
analysis (277) 277
myelodysplastic syndromes (275) 275
stem cells (273) 273
antineoplastic combined chemotherapy protocols - adverse effects (270) 270
pomalidomide (267) 267
animals (266) 266
research (264) 264
disease-free survival (263) 263
trial (263) 263
immunologic factors - therapeutic use (246) 246
abridged index medicus (241) 241
elderly-patients (241) 241
patients (241) 241
plus dexamethasone (241) 241
multiple myeloma - diagnosis (237) 237
angiogenesis inhibitors (232) 232
myeloma (231) 231
article (230) 230
retrospective studies (230) 230
rituximab (227) 227
immunology (215) 215
risk factors (215) 215
antineoplastic agents - adverse effects (209) 209
leukemia (208) 208
low-dose dexamethasone (207) 207
thalidomide - pharmacology (207) 207
carfilzomib (205) 205
cyclophosphamide (204) 204
clinical trials (203) 203
melphalan (197) 197
phase-ii (192) 192
survival analysis (192) 192
efficacy (190) 190
health aspects (188) 188
stem cell transplantation (186) 186
transplantation, autologous (186) 186
clinical trials as topic (182) 182
survival rate (178) 178
maintenance (176) 176
prednisone (171) 171
diagnosis (170) 170
combination therapy (169) 169
relapse (169) 169
antineoplastic agents - pharmacology (168) 168
hematopoietic stem cell transplantation (166) 166
immunotherapy (165) 165
autologous transplantation (164) 164
myelodysplastic syndrome (162) 162
myelodysplastic syndromes - drug therapy (162) 162
antineoplastic combined chemotherapy protocols - administration & dosage (161) 161
medicine, general & internal (161) 161
risk (160) 160
hemic and lymphatic diseases (158) 158
immunomodulatory drugs (158) 158
lymphomas (155) 155
antineoplastic agents - administration & dosage (153) 153
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3797) 3797
German (59) 59
French (40) 40
Polish (33) 33
Czech (19) 19
Russian (18) 18
Spanish (17) 17
Japanese (9) 9
Chinese (7) 7
Korean (4) 4
Hungarian (3) 3
Slovak (3) 3
Portuguese (2) 2
Turkish (2) 2
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Neri, P
BLOOD, ISSN 0006-4971, 07/2019, Volume 134, Issue 2, pp. 105 - 106
In this issue of Blood, Sperling et al describe the biological determinants underlying the activity of thalidomide analogs in a given cell and potential... 
LENALIDOMIDE | HEMATOLOGY | DEGRADATION
Journal Article
by Martin, A and Ngu, L
BRITISH JOURNAL OF HAEMATOLOGY, ISSN 0007-1048, 03/2019, Volume 185, pp. 176 - 176
Conference Proceeding
Leukemia & Lymphoma, ISSN 1042-8194, 05/2019, Volume 60, Issue 6, pp. 1584 - 1586
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 07/2019, Volume 25, Issue 13, pp. 3776 - 3783
Purpose: Pegylated liposomal doxorubicin (PLD) combined with bortezomib is an effective salvage regimen for relapsed refractory multiple myeloma (RRMM).... 
LENALIDOMIDE | FAMILY PROTEINS | BORTEZOMIB | ONCOLOGY
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2014, Volume 12, Issue 5.5, pp. 808 - 811
Studies on multiple myeloma reported in 2013 offer support for maintenance after induction and consolidation in newly diagnosed patients eligible for... 
ONCOLOGY | LENALIDOMIDE
Journal Article
HAEMATOLOGICA, ISSN 0390-6078, 01/2017, Volume 102, Issue 1, pp. 160 - 167
POEMS syndrome is a rare para-neoplastic syndrome secondary to a plasma cell dyscrasia. Effective treatment can control the disease-related symptom complex. We... 
EFFICACY | LENALIDOMIDE | THALIDOMIDE | HEMATOLOGY | MYELOMA
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 2019, Volume 42, Issue 5, pp. 294 - 295
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2017, Volume 28, Issue 11, pp. 2806 - 2812
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 06/2018, Volume 41, Issue 6, pp. 412 - 412
Journal Article
NATURE, ISSN 0028-0836, 08/2014, Volume 512, Issue 7512, pp. 49 - 49
In the 1950s, the drug thalidomide, administered as a sedative to pregnant women, led to the birth of thousands of children with multiple defects. Despite the... 
MULTIPLE-MYELOMA | CELLS | PROTEIN | MENTAL-RETARDATION | RECOGNITION | MULTIDISCIPLINARY SCIENCES | LENALIDOMIDE | CEREBLON | POMALIDOMIDE | CANCER | CONGENITAL ABNORMALITIES
Journal Article
JNCI: Journal of the National Cancer Institute, ISSN 0027-8874, 01/2019, Volume 111, Issue 1, pp. 7 - 8
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2015, Volume 13, Issue 5.5, pp. 666 - 669
As targeted therapy in B-cell lymphomas rapidly expands beyond anti-CD20 monoclonal antibodies, many newer types of agents are in various stages of... 
ONCOLOGY | INDOLENT LYMPHOMA | LENALIDOMIDE
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 09/2017, Volume 104, Issue 9, pp. 814 - 816
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 04/2017, Volume 40, Issue 4, pp. 226 - 227
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 02/2017, Volume 40, Issue 1-2, pp. 66 - 66
Journal Article
Investigational New Drugs, ISSN 0167-6997, 12/2018, Volume 36, Issue 6, pp. 1085 - 1092
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.